Stockwinners Market Radar for June 26, 2024 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

19:50 EDT Connexa Sports Technologies Inc trading halted, news pending

19:37 EDT CalciMedica jumps 21% after announcing conference call review Auxora trial - Shares of CalciMedica are up 21% afterhours at $5.65. Earlier this afternoon, the company announced that it will host a conference call on Thursday, June 27, 2024 at 8:30 a.m. ET/ 5:30 a.m. PT to discuss topline data from the Company's Phase 2b CARPO trial of Auxora in acute pancreatitis with accompanying systemic inflammatory response syndrome.

23:19 EDT FDA grants second approval for EPKINLY in r/r follicular lymphoma - AbbVie (ABBV) "announced that the FDA has approved EPKINLY, or epcoritamab-bysp, as the first and only T-cell engaging bispecific antibody administered subcutaneously for the treatment of adults with relapsed or refractory follicular lymphoma after two or more lines of prior therapy. This indication is approved under the FDA's Accelerated Approval program based on overall response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). Epcoritamab is being co-developed by AbbVie and Genmab (GMAB) as part of the companies' oncology collaboration. The companies will share commercial responsibilities in the U.S. and Japan, with AbbVie responsible for further global commercialization. FDA approval is based on results from the Phase 1/2 EPCORE NHL-1 clinical trial, which evaluated the safety and efficacy of EPKINLY in 127 adult patients with R/R FL who previously received a median of three lines of therapy and with 70% having double refractory disease. Results and safety findings include: The study results showed an overall response rate - the study's primary endpoint - of 82%, a complete response rate of 60% and a partial response rate of 22%. At a median follow-up of 14.8 months among responders, more than half of patients who responded to treatment in the study remained responsive to treatment. The safety of EPKINLY at a target dose of 48 mg was evaluated in EPCORE NHL-1, a single-arm study of 127 patients who received a 2-step up dosage schedule. The most common (greater than or equal to20%) adverse reactions were injection site reactions, cytokine release syndrome, COVID-19, fatigue, upper respiratory tract infection, musculoskeletal pain, rash, diarrhea, fever, cough, and headache. A separate dose optimization cohort evaluated 86 patients at the recommended 3-step dosage schedule for CRS mitigation. For the first full dose of this 3-step regimen, mandatory hospitalization was not required. There were no grade 3 CRS observed in patients with FL who received EPKINLY with the 3 step-up dosage schedule."

23:05 EDT Suzano will not pursue acquisition of International Paper - The company states: "Suzano (SUZ), in compliance with of Law No. 6.404, of December 15th, 1976, as amended, Resolution No. 44, of August 23rd, 2021, and CVM Resolution No. 80, of March 29th, 2022, as amended, in line with the best corporate governance practices and following up on the Material Fact disclosed on May 22nd, 2024, informs its shareholders and the market in general that, after some negotiations with the International Paper (IP) regarding a potential transaction between the companies, the Company has reached what it believes to be the maximum price for the transaction to generate value for Suzano, without engagement from the other party. Therefore, in observance of its commitment to capital discipline, Suzano formalizes that it will not pursue a transaction involving the acquisition of International Paper. It is important to emphasize that it has always been a condition of Suzano for the completion of this transaction that the engagement between the parties be based on private, confidential, and amicable terms. As it was not possible to proceed in this manner, Suzano has decided to terminate the negotiations.

18:55 EDT MongoDB director sells $2.28M in common stock - In a regulatory filing, MongoDB disclosed that its director John McMahon sold 10K shares of common stock on June 24th in a total transaction size of $2.28M.

18:31 EDT Novonix granted patent for all-dry cathode synthesis in Japan - Novonix has been granted a patent for its proprietary all-dry, zero-waste cathode synthesis technology in Japan. This patent utilizes Novonix's all-dry, zero-waste cathode processing to produce single-crystal NMC powders. The company currently has 10 families of cathode process patent applications in various stages of examination across different jurisdictions.

17:56 EDT UL Solutions to build Advanced Automotive and Battery Testing Center in Korea - UL Solutions "announced plans to construct a new Advanced Automotive and Battery Testing Center in Pyeongtaek, Gyeonggi-do, Korea, expanding current UL Solutions battery testing capacity in the region and adding electric vehicle charger testing and other capabilities. To serve customers across the Asia Pacific region, the center, expected to open in the second half of 2025, will help strengthen Korea's EV industry, respond to increased demand from new and existing customers, and provide faster access to safety and performance testing and other services. The new facility, construction of which is subject to local government approvals, including zoning, will provide expanded EV battery testing capacity. This laboratory will leverage the technology used in the recently opened UL Solutions Korea Advanced Battery Laboratory in Pyeongtaek to test for reliability and performance. Plans also include an EV charger testing laboratory and an EV battery material laboratory. In addition, the center will be built to test automotive plastic safety, including flammability and performance, with technology in use in UL Solutions in the U.S."

21:33 EDT Regeneron/Sanofi announce NEJM publication of Dupixent Phase 3 EoE results - The company states: "Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) announced the New England Journal of Medicine, or NEJM, has published results from a positive Phase 3 trial for Dupixent, or dupilumab, in children aged 1 to 11 years with eosinophilic esophagitis, or EoE. The trial showed a greater proportion of those receiving weight-tiered higher dose Dupixent experienced significant improvements in many key disease measures of EoE, compared to placebo at week 16. Data from the trial were the basis for the U.S. Food and Drug Administration Priority Review and approval of Dupixent in children aged 1 to 11 years with EoE weighing at least 15 kg, as well as for the regulatory submission that is currently under review by the European Medicines Agency for this age group. EoE is a chronic, progressive disease associated with type 2 inflammation that is thought to be responsible for damaging the esophagus and impairing its function. Diagnosis is difficult, as symptoms can be mistaken for other conditions and there are delays in diagnosis. EoE can severely impact a child's ability to eat and may also cause abdominal pain, trouble swallowing, heartburn, vomiting and failure to thrive. Continuous management of EoE may be needed to reduce the risk of complications and disease progression. As published, a significantly greater proportion of children receiving either a weight-tiered higher or lower dose regimen of Dupixent achieved histologic remission at week 16 in Part A of the trial, compared with placebo. Additionally, those treated with higher dose Dupixent experienced significant improvements in disease severity assessed by endoscopic measures, with improvements sustained for up to one year. Those receiving lower dose Dupixent experienced improvements that were either comparable or numerically lower than the higher dose group. Dupixent also led to a numerical improvement in body weight for age percentile by week 16 that was sustained at one year, which was evaluated as an exploratory endpoint in Part A and a secondary endpoint in Part B. Safety results were generally consistent with the known safety profile of Dupixent in adolescents and adults with EoE. Adverse events more commonly observed with Dupixent (10%) in either weight-based dosing regimen versus placebo in the trial were COVID-19, nausea, injection site pain and headache during Part A. The long-term safety profile of Dupixent in children aged 1 to 11 years through Part B was similar to that observed during Part A. In Part B, one case of helminth infection was reported with Dupixent."

17:30 EDT Verona Pharma trading resumes

17:19 EDT American Electric appoints Bill Fehrman as President and CEO - American Electric elected William Fehrman as President and CEO, effective Aug. 1. Fehrman most recently served as president and CEO of Centuri Holdings. Prior to that, he was president and CEO of Berkshire Hathaway Energy. Fehrman also led MidAmerican Energy Company, PacifiCorp Energy and Nebraska Public Power District as president and CEO. Fehrman will succeed Ben Fowke, who has been serving as interim CEO since February. Fowke, who was elected to the Board in 2022 and will continue as a board member, will serve as a senior advisor for several months to ensure a smooth transition. AEP also announced that Linda Goodspeed is retiring from AEP's Board of Directors, effective July 31.

17:16 EDT Centuri CEO Bill Fehrman stepping down - Centuri Holdings (CTRI) announced Bill Fehrman will be stepping down as president and CEO to take the CEO role at American Electric Power ( AEP), one of the nation's largest publicly traded utility companies. He will continue in his role as President and CEO of Centuri until July 31. The Centuri board has appointed Paul Caudill, former CEO of NV Energy, a Berkshire Hathaway Energy portfolio company, and senior advisor to the CEO and prior Centuri advisory board member, to succeed him as interim president and CEO. Additionally, Fehrman will remain on Centuri's board until the company transitions to a permanent CEO.

17:01 EDT i3 Verticals to sell merchant of record payments business for $440M - i3 Verticals and Payroc WorldAccess announced that the companies have entered into a definitive agreement whereby Payroc will acquire i3 Verticals' merchant of record payments business, including its associated proprietary technology, in an all-cash transaction for $440M, subject to certain purchase price adjustments. The transaction is subject to closing conditions as set forth in the definitive agreement, including the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976. The closing is expected to occur sometime in i3 Verticals' fiscal fourth quarter.

17:00 EDT Verona Pharma announces FDA approval of Ohtuvayre - Verona Pharma announces the U.S. FDA approved Ohtuvayre for the maintenance treatment of chronic obstructive pulmonary disease in adult patients. Ohtuvayre is the first inhaled product with a novel mechanism of action available for the maintenance treatment of COPD in more than 20 years. The company is fully staffed to launch and expects Ohtuvayre to be available in the third quarter 2024 through an exclusive network of accredited specialty pharmacies.

16:59 EDT HashiCorp's Dadgar sells $708K in company shares - HashiCorp director Armon Dadgar disclosed in a filing that had sold 21,137 shares of company stock at $33.48 per share on June 24, for a total transaction amount of $707,576.

16:57 EDT Verona Pharma trading halted, news pending

16:53 EDT Crown Electrokinetics issues shareholder letter, effected 1:150 reverse split - The company states: "Dear Fellow Shareholders, This letter is an update to investors regarding Crown's Nasdaq listing and operational updates for the Electrokinetic Film and Fiber Construction Divisions. In line with Nasdaq's compliance requirements and timing, Crown effected a 1:150 reverse split yesterday to maintain our listing. While we would have preferred to delay the reverse split and deliver organic price appreciation, we are bound to a strict compliance deadline from Nasdaq. We remain focused on growing the company and building long-term shareholder value through the continued execution of our strategic goals. Crown's Fiber Optics division's strong growth continues with production in the second quarter delivered in each of our Nevada, Idaho, Oregon, Arizona and Florida markets. We announced in a press release earlier this week that we are expanding our work in Idaho as the prime contractor building our customers fiber network. We have also been awarded additional work and expect the relationship to grow both within and beyond Idaho. In Nevada, we are midway through our long-haul project and believe we will be securing work for this customer in New Mexico and California in the coming months. As previously announced this week we are aggressively expanding in Oregon with four new customers and are now in discussions with a new partner to handle work in Portland, Phoenix, Arizona and Las Vegas as a prime vendor for two of the largest cable and telecommunications operators in the country. More details will be available on this project in the coming days. We now expect our revenue for the second quarter will come in between $3.5 million and $4 million and expect third quarter revenues of between $7 million and $8 million stemming from the current backlog. Within the Electrokinetic Film division, we continue to make progress and move towards our Alpha Gen 1 product delivery in the fall of this year. We will have some additional announcements in the coming days discussing additional executive management additions and product development milestones."

16:51 EDT Geospace joins Russell 2000, Russell 3000 indices - Geospace Technologies announced that as part of the annual reconstitution of the Russell stock indexes, the Company will be added to the Russell 2000(R), Russell 3000(R), and Russell Micro-Cap(R) Index which will be effective on July 1, 2024.

16:36 EDT Aterian co-CEO Joe Risico resigns, Josh Feldman named CFO - Aterian announced the appointment of Arturo Rodriguez as CEO and Josh Feldman as CFO and that Joe Risico has resigned as co-CEO and from the board of directors and will consult the company over a three-month transition period. "Joe and I have enjoyed a remarkable partnership over the years, and the strategic decisions we have made together as Co-CEOs have significantly strengthened Aterian's trajectory. On behalf of the entire Aterian team, we extend our heartfelt appreciation for Joe's dedication, and unwavering commitment. We wish Joe ongoing success in his future ventures and I am excited for him to start his next chapter," said Arturo Rodriguez, Aterian's CEO.

16:34 EDT Reborn Coffee intends to appeal delisting notice from Nasdaq - Reborn Coffee announced that it has received a notice of delisting from Nasdaq. On June 21, Reborn Coffee the received a staff determination letter from the Nasdaq Listing Qualifications Staff of The Nasdaq Stock Market notifying the Company that because it has not yet filed its Form 10-Q for the fiscal year ended March 31 it has failed to comply with the filing requirement set forth in Listing Rule 5250(c.)(1). As previously announced on May 15, the company was required to dismiss BF Borgers CPA PC as the company's independent registered public accounting firm. The company was required to engage a new independent registered public accounting firm in order to complete and file the Form 10-Q.

16:29 EDT AeroVironment falls 7% to $178.80 after Q4 results, initial FY25 guidance

16:29 EDT AeroVironment CEO says Loitering Munitions Segment remains key growth driver - "AeroVironment has yet again delivered exceptional results this past quarter resulting in record revenue and full year profitability for the company," said Wahid Nawabi, CEO. "We are pleased to also announce our full year revenue increased 33% from last year's results. Our Loitering Munitions Segment continues to be a key growth driver for our company, and we have expanded capacity to deliver these much-needed systems to keep up with increasing customer demand. As the need for our autonomous systems continues to rapidly increase worldwide, AeroVironment stands ready to meet our customer's needs while delivering solid bottom-line results for our shareholders. We are therefore issuing fiscal year 2025 revenue guidance of between $790 million and $820 million, another record year and double-digit revenue increase from fiscal year 2024."

16:23 EDT Casi Pharmaceuticals receives acquisition proposal for its entire China business - Casi Pharmaceuticals' board received a preliminary non-binding proposal letter from CEO and Chairman of the company of the Board Wei-Wu He, to acquire the entire business operations of the company in China and all license-in, distribution and related rights in Asia - excluding Japan - related to all of the company's pipeline products for an aggregate purchase price of $40.0M, which shall include assumption of up to $20.0M of indebtedness of the company. The Board has formed a special committee comprised solely of incumbent independent directors to evaluate the transaction and other strategic and business alternatives available to the company in respect of the company's business operations in China. No decisions have been made with respect to the Proposed Transaction or any alternative strategic option that the company may pursue.

16:22 EDT H.B. Fuller sees Q3 adjusted EBITDA $165M-$175M vs. $156M last year

16:19 EDT Conn's announces receipt of delinquency notification letter from Nasdaq - Conn's announced that on June 20, it received a delinquency notification letter from the Nasdaq Stock Market, indicating that the company was not in compliance with Nasdaq Listing Rule 5250c1 because of the company's delay in filing its Quarterly Report on Form 10-Q for the fiscal quarter ended April 30 by the applicable due date required by the U.S. Securities and Exchange Commission. The Notice has no immediate effect on the listing or trading of the Company's common stock on The Nasdaq Global Select Market.

16:18 EDT Jefferies Financial Group raises quarterly dividend by 17% to 35c per share - The dividend is payable on August 30, 2024 to record holders of Jefferies common shares on August 19, 2024.

16:16 EDT Bellevue Capital raises purchase price for shares of American Strategic Investment Co. - Bellevue Capital Partners announced that it has increased the purchase price of its previously announced tender offer to purchase up to 125,000 shares of American Strategic Investment Co. common stock from the previous purchase price of $10.25 to an increased purchase price of $11.00 per share. The Tender Offer will close on July 5, 2024. Bellevue is making this offer at a 90% premium to the May 3, 2024 closing price because of its continued confidence in ASIC's portfolio and underlying assets. Bellevue further believes in the previously announced expanded investment strategy that ASIC is pursuing and in the long-term value of ASIC's common stock. The 90% premium to the May 3, 2024 closing stock price reflects Bellevue's belief in the long-term performance of ASIC and its portfolio of assets.

20:15 EDT 2seventy Bio announces sale of Hemophilia A candidate for up to $40M - 2seventy bio. (TSVT) announced the completion of an asset purchase agreement by Novo Nordisk (NVO). Under the terms of the APA, Novo Nordisk has acquired the Hemophilia A program and rights to 2seventy's in vivo gene editing technology outside of oncology and gene editing for autologous or allogeneic cell therapies of immune cells for the treatment of autoimmune disease. The 2seventy bio team currently involved in the program will join Novo Nordisk and continue to advance the technology. The program is based on the original research agreement, established in 2019, which focused on a gene editing therapy for people with Hemophilia A. 2seventy bio will focus exclusively on the commercialization and continued development of Abecma (idecabtagene vicleucel), its BCMA-targeted CAR T cell therapy for multiple myeloma, in collaboration with Bristol Myers Squibb (BMY). Under the terms of the agreement, 2seventy will potentially receive payments of up to $40 million. 2seventy will transfer the Hemophilia A program to Novo Nordisk and the existing collaboration agreement will terminate. Additionally, the divestiture will include transfer of 2seventy bio's megaTAL technology and a license to underlying intellectual property.

16:10 EDT State Street Global Advisors to partner with Galaxy Digital Holdings - State Street Global Advisors and Galaxy Asset Management, an affiliate of Galaxy Digital Holdings Ltd. and one of the world's largest digital assets and blockchain investment managers, "announced they are collaborating to bring investors the next generation of digital asset based strategies that will offer exposure to companies involved in the digital asset space, going beyond cryptocurrencies and bitcoin. This collaboration of market-leading, global asset managers is designed to bring investors the newest innovation in digital asset investing. By combining the strengths of two of the biggest brands and first-movers, State Street Global Advisors and Galaxy Asset Management will provide investors access to the $2.4 trillion digital asset ecosystem through manager-directed strategies."

16:08 EDT Marathon Digital announces Kaspa mining operations - Marathon Digital Holdings announced that the company is mining Kaspa or KAS, a proof-of-work, PoW, digital asset, to further diversify its portfolio of digital asset compute. Kaspa is currently the fifth largest proof-of-work digital asset by market cap. It boasts a market cap of $3.9B with approximately $64.8M in daily trading volume as of June 25. The circulating supply is approximately 24 billion KAS with a current block reward of 103.83 KAS, and the terminal supply is capped at 28.7B KAS. Similar to Bitcoin, Kaspa is an open-source, decentralized, and fully scalable Layer-1 protocol that uses proof-of-work as its consensus mechanism. However, unlike Bitcoin's blockchain, which is linear and processes one block every ten minutes, Kaspa utilizes a BlockDAG that enables multiple blocks to be produced simultaneously. The Kaspa network currently processes one block every second, allowing for faster transactions and providing Kaspa miners with the opportunity to potentially earn more block rewards in a given time frame. In May 2023, Marathon began evaluating Kaspa as a potential way to diversify its revenue while continuing to utilize its current infrastructure and expertise in digital asset compute. After successfully deploying its first Kaspa ASICs in September 2023, the Company began scaling its operations. As of June 25 Marathon has mined 93 million KAS, which are currently valued at approximately $15M.

16:07 EDT Franklin Covey sees FY24 adjusted EBITDA at low end of $54.5M-$58M range - Based on the Company's third quarter results, combined with improved leading indicators and the Company's current expectations regarding the fourth quarter, the Company looks forward to a strong finish to fiscal 2024. Despite the challenges the Company faced in the first half of fiscal 2024, the Company continues to expect that its Adjusted EBITDA for fiscal 2024, while showing a strong increase in the third quarter, will be at the low end of its previously announced guidance range of $54.5 million to $58.0 million in constant currency, which excludes the impact of approximately $0.5 million of negative foreign exchange. This represents 13% growth over the $48.1 million of Adjusted EBITDA achieved in fiscal 2023. The Company expects to achieve this growth despite an uncertain economic environment and while continuing to make additional growth investments. The Company is also confident in the strength of its subscription offerings, which have driven Franklin Covey's growth across recent years, and which are expected to deliver in fiscal 2024 the highest levels of revenue, Adjusted EBITDA, and Free Cash Flow since the sale of the Company's consumer products division.

16:04 EDT Quest Diagnostics to acquire lab assets from Allina Health - Quest Diagnostics and Allina Health, a non-profit health care system, announced a definitive agreement for Quest to acquire select laboratory assets from Allina Health, with the goal to improve access to and the affordability of innovative laboratory services across Minnesota and western Wisconsin. Quest will offer its laboratory services to Allina Health clinic physicians and outreach provider clients across Minnesota and western Wisconsin. Quest Diagnostics and Allina Health expect to complete the transaction in Q3, assuming customary regulatory reviews. Financial details were not disclosed.

15:51 EDT Ennis announces acquisition of Printing Technologies, Inc. - Ennis announced its acquisition of Printing Technologies, Inc. located in Indianapolis, a manufacturer of media solutions used in all types of Printing Technologies including direct thermal, thermal transfer, ink jet, dot matrix and laser. "PTI is a renowned brand with a diverse range of unique products and we are looking forward to leveraging these new capabilities to enhance Ennis' product offerings. I want to extend a warm welcome to PTI's employees and customers as they join the Ennis family," said Keith Walters, Chairman, President and CEO of Ennis.

15:28 EDT Singular Genomics Systems trading resumes

19:12 EDT Attorneys announce complaints filed with FAA, OSHA against Boeing and Spirit - Attorneys Debra Katz and Lisa Banks announced they filed complaints with the Federal Aviation Administration and the Occupational Health and Safety Administration on behalf of airplane mechanic Richard Cuevas, who is identified as a 40-year veteran of the airline industry. "Mr. Cuevas, who was contracted to Spirit to repair Boeing aircraft, alleges that he witnessed substandard manufacturing and maintenance processes on the 787 forward bulkhead, including critical drilling and sealant issues. Mr. Cuevas complained that these safety issues, if unremedied, could compromise power and air pressure on the planes, creating a serious public safety risk. When he raised these issues - first with Spirit management and then with Boeing's ethics program - he was fired," the attorneys stated. Reference Link

14:22 EDT JetBlue names Tracy Lawlor chief people officer - JetBlue announced the appointment of Tracy Lawlor to chief people officer, effective immediately. Lawlor, a veteran of the airline for nearly 23 years, has served as acting chief people officer since March 2024. Reporting to JetBlue's CEO, Joanna Geraghty, Lawlor will be responsible for engaging JetBlue crewmembers and fostering its unique culture, overseeing teams such as compensation and benefits; diversity, equity and inclusion; crew relations; culture; values and labor relations; recruiting and talent management. "Tracy is an experienced leader known for her ability to turn strategic visions into reality while fostering strong collaboration across the airline," said Geraghty. "Her deep understanding of our business as well as her passion for our mission and values make her the ideal leader to help guide our people and culture as we execute our strategy and set up JetBlue for long-term success."

17:27 EDT PDD Holdings down 2% after Information report on Amazon plans for Temu rival

12:02 EDT FedEx rises 14.1% - FedEx is up 14.1%, or $36.23 to $292.61.

12:01 EDT Tecnoglass rises 20.7% - Tecnoglass is up 20.7%, or $8.51 to $49.54.

12:01 EDT Rayonier Advanced Materials falls -7.5% - Rayonier Advanced Materials is down -7.5%, or -42c to $5.18.

11:56 EDT Vicor reports court grants preliminary injunction against Foxconn subsidiaries - Vicor Corporation announced that, on June 24, the United States District Court for the District of Massachusetts granted a preliminary injunction barring subsidiaries of Foxconn from pursuing arbitration against Vicor before the China International Economic and Trade Arbitration Commission, or "CIETAC." Vicor stated: "The Foxconn subsidiaries had sought to obtain a ruling from CIETAC that small print in their purchase orders for Vicor power modules entitled them to royalty-free licenses to Vicor patents, including patents asserted in a pending investigation in the United States International Trade Commission, or 'ITC.' An ITC exclusion order could bar from entry into the United States infringing power converter modules, 'NBMs,' and systems containing such modules, including artificial intelligence accelerators, tensor processing units, 'TPU,' graphical processing units, 'GPU,' and central processing units, 'CPU,'."

11:30 EDT Rapid7 up 8% after WSJ says activist Jana built stake, pushing for sale

11:09 EDT Elliott 'committed to delivering' leadership changes at Southwest - Elliott Investment Management released the following statement on behalf of Partner John Pike and Portfolio Manager Bobby Xu regarding Southwest Airlines Co. and its revenue guidance reduction announcement: "Today's announcement marks the eighth guidance reduction at Southwest Airlines in the last 18 months with RASM now expected to decline 4% to 4.5% in the second quarter, a significant reduction relative to the guidance that Southwest's management team provided only two months ago. Southwest's industry-trailing revenue performance is clearly continuing along the same disappointing trend line, despite management's repeated promises for improvement and today's empty statement that the Company is focusing on 'delivering operational excellence.' Southwest is led by a team that has proven unable to adapt to the modern airline industry; the Company's release today seems to admit as much by stating that the revenue guidance reduction was the result of 'complexities in adapting; to the current environment - complexities that Southwest's peers seem able to adapt to. Unfortunately, this is yet another example that fundamental leadership change is urgently needed at Southwest. Elliott is committed to delivering the leadership changes that the Company requires."

10:55 EDT Novo Nordisk stops CLARION-CKD trial, recognizes DKK 5.7B impairment loss - Novo Nordisk announced that the CLARION-CKD phase 3 trial failed to meet its primary endpoint and that it will recognize an impairment loss of around DKK 5.7B related to the intangible asset ocedurenone in the second quarter of 2024. "Novo Nordisk acquired ocedurenone from KBP Biosciences PTE., Ltd. in 2023. The phase 3 lead indication trial CLARION-CKD, which investigated ocedurenone in patients with uncontrolled hypertension and advanced chronic kidney disease, was conducted by KBP Biosciences. The trial design included a prespecified interim analysis after all trial participants had completed 12 weeks of treatment. Based on the interim analysis, an independent data monitoring committee concluded that the trial met the prespecified futility criteria - meaning that the trial did not meet its primary endpoint of change in systolic blood pressure from baseline to week 12. As a result, Novo Nordisk has decided to stop the CLARION-CKD trial. Consequently, Novo Nordisk will recognise an impairment loss of around DKK 5.7 billion. This corresponds to an estimated negative impact of around 6 percentage points on operating profit growth at CER in 2024 compared to the operating profit outlook communicated in the financial report for the period 1 January 2024 to 31 March 2024. Novo Nordisk's disclosure of the financial results for the first six months of 2024 and financial outlook for 2024 will be published on 7 August," the company stated.

10:37 EDT Masimo urges stockholders to vote for nominees Joe Kiani, Christopher Chavez - Masimo Corporation filed an investor presentation with the U.S. Securities and Exchange Commission in connection with its Annual Meeting of Stockholders to be held on July 25, 2024. The company said, "The presentation lays out in detail: The Company's robust track record of innovation, led by Masimo Founder, Chairman and CEO Joe Kiani, that supports Masimo's longstanding valuation premium to industry peers; Masimo's strategic initiatives for sustained growth and margin expansion that are expected to more than double adjusted EPS to ~$8 by 2029; and The Company's belief that Politan's value-destructive agenda to oust Mr. Kiani and take control of Masimo without paying a premium or articulating an exercisable plan poses a significant risk to the value of the Company. To safeguard stockholders' investments and ensure continued value creation, the Board strongly recommends that stockholders vote FOR Masimo's highly qualified director nominees, Joe Kiani and Christopher Chavez."

10:34 EDT Vital Farms to build egg washing, packing facility in Seymour, Indiana - Vital Farms has announced plans to expand its resilient supply chain with a second world-class egg washing and packing facility located in Seymour, Indiana. The 72-acre future home of Egg Central Station Seymour will build upon key successes from the brand's first facility in Springfield, Missouri. The new facility will enable Vital Farms to continue growing its pasture-raised egg business, create 150+ jobs for the Seymour community in its first phase, and is expected to help generate over $350 million in additional revenue for the brand as we push to our 2027 target of $1 billion in company revenues. Putting down roots in Seymour for Vital Farms' second facility allows the brand to continue to expand its strong network of more than 300 family farms to support new farm development within a day's drive of the new facility. Vital Farms expects this new facility, in its first phase, will support approximately 165 family farmers producing the leading U.S. brand of pasture-raised eggs by retail dollar sales. ECS Seymour is expected to break ground mid-2025 and be fully operational at the beginning of 2027.

10:29 EDT GitLab up 11% after board adopts amendments to severance plan - In a regulatory filing, GitLab disclosed that on June 22, the board of directors of the company adopted amendments to the company's existing severance plan, applicable to certain team members of the company, including the company's named executive officers, in connection with a periodic review of the plan. "The amendments to the Plan include an amendment to the definition of "CIC Severance" to clarify that an individual's equity awards may not be subject to cancellation by the Board in connection with a Corporate Transaction (as defined in the Plan) without consideration," the filing stated. In Wednesday morning trading, shares of GitLab are up $4.62, or 11%, to $48.22. Reference Link

10:12 EDT Safety Shot partners with Atlantic Beverage Distributors - Safety Shot announced its strategic partnership with Atlantic Beverage Distributors. This collaboration aims to expand the reach of Safety Shot's innovative product to additional key markets in the Northeastern region. Headquartered in Holliston, Massachusetts, Atlantic Beverage Distributors has been a key player in the distribution industry since its founding in 1995. The company began with a mission to distribute specialty beer and wine not represented by volume wholesalers, and it has since evolved to feature the most sought-after brands.

10:08 EDT Moderna falls 6% ato $130.03 after RSV vaccine data

10:01 EDT Whirlpool rises 14.5% - Whirlpool is up 14.5%, or $12.61 to $99.64.

10:01 EDT Worthington falls -6.3% - Worthington is down -6.3%, or -$3.15 to $47.01.

10:00 EDT Global Blue falls -6.7% - Global Blue is down -6.7%, or -34c to $4.77.

09:49 EDT Vsee Health Inc trading resumes

09:47 EDT TXO Energy Partners falls -8.7% - TXO Energy Partners is down -8.7%, or -$1.90 to $20.03.

09:47 EDT FedEx rises 11.6% - FedEx is up 11.6%, or $29.85 to $286.23.

09:47 EDT Tecnoglass rises 19.3% - Tecnoglass is up 19.3%, or $7.92 to $48.95.

09:44 EDT Bite Acquisition Corp trading halted, volatility trading pause

09:43 EDT Nano Nuclear Energy Inc trading resumes

09:41 EDT Volcon Inc trading resumes

09:36 EDT Volcon Inc trading halted, volatility trading pause

09:33 EDT Nano Nuclear Energy Inc trading halted, volatility trading pause

09:32 EDT Tempus AI receives 510(k) clearance for Tempus ECG-AF - Tempus AI has received 510(k) clearance from the U.S. Food and Drug Administration for its Tempus ECG-AF device that uses AI to help identify patients who may be at increased risk of atrial fibrillation/flutter. This is the first FDA clearance for an AF indication in the category known as "cardiovascular machine learning-based notification software" and paves the way for physicians to use this innovative algorithm in the care of their patients.

09:21 EDT Genius Sports secures UEFA deal for player tracking technology - The company states: "On June 15, 2024, Genius Sports Limited secured an agreement with the Union of European Football Associations, or UEFA, to provide centre of mass player tracking technology to UEFA for the UEFA Europa League - seasons 2024/2025 to 2026/2027 inclusive - and the UEFA European Qualifiers and UEFA Nations League, 2024/25 to 2027/2028 seasons inclusive. This agreement will span 1,350 matches and see Genius Sports' AI technology installed at over 140 stadiums."

09:18 EDT Cyclacel Pharmaceuticals receives notice of intention to grant European patent - Cyclacel Pharmaceuticals announced the receipt of a notice from the European Patent Office of the intention to grant a patent which includes claims to novel pharmaceutical compositions of plogosertib, a PLK1 inhibitor. Once granted, the European patent will provide exclusivity until August 2040 not including any extensions. The Company is prosecuting patent applications from the same family in other jurisdictions.

09:17 EDT Goldenstone Acquisition, Infinitium enter business combination agreement - Goldenstone Acqusition and Infintium Fuel Cell Systems have entered into a definitive business combination agreement under which Goldenstone will combine with Infintium. Upon completion, the combined company will operate as Infintium Fuel Cell Systems Holdings, Inc. and its common stock is expected to be publicly listed on The Nasdaq Stock Market. Infintium's patent-pending and proprietary hydrogen fuel cell products, which include Class I, II and III electric forklift trucks and compatible with major forklift brands, provide carbon-free power source for material handling vehicles. The Company's fuel cell systems, operated with in-house developed software algorithms and DC/DC power controls, bring superior performances with longer operating time, steeper hill climbing, real-time, millisecond data acquisition and monitoring, remote diagnostics and fault detection capabilities. Infintium's fuel cells have been tested and proven in over 1.8 million hours of run time under harsh and challenging industrial operating environments. Its customers and end users include Fortune 500 industrial and automotive companies, such as Mercedes-Benz, Ford, and BMW, as well as some of the largest retail and e-commerce companies in the world. Under the terms of the Business Combination Agreement, the transaction values Infintium at a pre-money enterprise value of $130 million. The Business Combination would provide approximately $18 million in gross cash proceeds to Infintium at closing, before transaction expenses and assuming no redemptions of shares by Goldenstone's existing public stockholders. Existing Infintium stockholders are rolling 100% of their equity into the combined company post Business Combination. The proceeds from the Business Combination will be used for Infintium to secure new manufacturing facilities and expand its sales and marketing operations. Each of the board of directors of Infintium and Goldenstone have approved the proposed Business Combination, the consummation of which is subject to various customary closing conditions, including the filing and effectiveness of a Registration Statement on Form S-4 with the Securities and Exchange Commission, and the approval of the stockholders of Infintium and Goldenstone. Completion of the proposed Business Combination is expected to happen by the first quarter of 2025.

09:15 EDT Hayward acquires pool water sanitization firm ChlorKing, no terms - Hayward Holdings announced the acquisition of ChlorKing , a U.S. market leader in commercial pool saline chlorinators and UV disinfection systems.This strategic acquisition advances Hayward's technology for commercial swimming pool water treatment, broadens its commercial product offering, and underscores its commitment to enhancing leadership in sustainable water management and treatment. ChlorKing is renowned for its leadership in on-site chlorine generation, commercial saline systems and UV disinfection systems for sanitizing swimming pools and other recreational bodies of water. "We are thrilled to welcome the ChlorKing team to Hayward. Under Steve Pearce's leadership, ChlorKing has established itself as a leader in commercial pool and recreational water treatment. This acquisition emphasizes our commitment to embracing technology that delivers sustainable, energy-efficient, and easy-to-use solutions for commercial pool operators and residential homeowners..."

09:13 EDT KindlyMD announces SAM.gov registration, grant application - KindlyMD announced its registration on SAM.gov, the official U.S. federal funding platform. The System for Award Management is a U.S. government website that provides contractors and organizations the ability to register and apply for federal grants, renew contracts, and access data to support their grant application processes. This pivotal achievement not only enables KindlyMD to obtain funds for federal grants and contracts, including those with the Department of Veterans Affairs, but also opens the door to a broad spectrum of federal funding opportunities crucial for advancing its mission of providing comprehensive healthcare solutions. Following the Company's SAM.gov registration, KindlyMD submitted its first grant application for the United States Department of Agriculture Rural Utilities Service Distance Learning and Telemedicine Grant Program. Submitted on April 27, 2024, this application seeks to secure funding to expand the Company's Complete Care telehealth program in rural communities in Utah. This innovative program combines traditional primary care with pain management strategies and mental health services to deliver comprehensive telehealth treatment across Utah's rural communities. The program's goal is to deliver effective healthcare through an interconnected network of telemedicine clinics, addressing the unique challenges faced by rural populations. The fiscal year 2024 DLT grant application period closed on April 29, 2024, with KindlyMD applying for the full $1,000,000 grant to implement distance learning and telemedicine systems that will provide vital educational and medical services to remote communities.

09:12 EDT Comtech awarded $30M contract from North Central Texas - Comtech announced the North Central Texas Emergency Communications District awarded the company a contract to deliver Next Generation 9-1-1, or NG9-1-1, services that will further modernize NCT9-1-1's infrastructure. The NCT9-1-1 contract includes a five-year base award, as well as three additional two-year option periods, with a not to exceed value of approximately $30M. Comtech has partnered with NCT9-1-1 for over 10 years and the company currently provides a wide range of call routing and call handling technologies serving over two million people in Texas. NCT9-1-1 is responsible for 40-plus Emergency Communications Centers in 13 counties and five municipalities surrounding the Dallas/Fort Worth Metroplex. Through this new contract, Comtech's suite of public safety solutions will enable NCT9-1-1 to fully migrate to a new NG9-1-1 system. Comtech will also continue to enhance the region's call routing capabilities by providing major NG9-1-1 sub-components, including Next Generation Core Services, Emergency Services Internet Protocol Network and Call Aggregation, among other services.

09:11 EDT Methes Energies begins certification process for b2 biOil marine lubricants - Methes Energies confirmed the pursuit of National Marine Manufacturers Association engine oil certification. TC-W3 certification for 2-stroke marine engines; and, FC-W and FC-W Catalyst Compatible for 4-stroke cycle, water cooled gasoline engines for their assortment of b2 biOil marine bio-lubricants. As the leading certification body for the recreational boating industry in the USA, NMMA Certification impacts the recreational marine industry worldwide, helping to improve boat manufacturing and ensure quality products for consumers throughout the world. The United States Environmental Protection Agency has outlined the properties of Environmentally Acceptable Lubricants targeting three primary environmental traits; biodegradability, aquatic toxicity and bioaccumulation...all b2 biOils meet these standards, including "readily biodegradable," an arbitrary classification of chemicals which have passed certain specified screening tests for ultimate biodegradability. These tests are so stringent that it is assured that such components will rapidly and completely biodegrade in aquatic environments under aerobic conditions. In addition, the Vessel General Permit requires vessels to use EALs in all oil-to-sea interfaces as EALs minimize their likely adverse consequences in an aquatic environment.

09:08 EDT NeuroBo Pharmaceuticals doses first patient in MAD Part 2 of DA-1726 trial - NeuroBo Pharmaceuticals announced dosing of the first patient in the multiple ascending dose Part 2 of its Phase 1 clinical trial of DA-1726, a novel, dual oxyntomodulin analog agonist that functions as a glucagon-like peptide-1 receptor and glucagon receptor, for the treatment of obesity. The company anticipates reporting top-line data from the SAD Part 1 during the third quarter of this year, and from the MAD Part 2 in the first quarter of 2025.

09:07 EDT TruGolf signs exclusive licensing deal with Golf Blueprint - TruGolf announced a multi-year exclusive licensing partnership with Golf Blueprint. The agreement will make Golf Blueprint's patent-pending technology available to E6 APEX Subscribers. This exclusive partnership will give E6 APEX users access to Golf Blueprint's structured lesson plans that take the guesswork out practice and provide structured and measured plans inside of TruGolf's software. "This partnership marks the beginning of an exciting journey for our customers," said TruGolf CEO Chris Jones. "We could not ask for a better partner in our continued effort to make it easy for golfers to improve. The results speak for themselves - Golf Blueprint users lower their handicap and achieve incredible things on the golf course."

09:07 EDT Bit Origin provides updates on collaborations with Aethir - Bit Origin provides an update on its collaborations with Aethir, the premier enterprise-focused distributed graphics processing units, GPU, cloud provider. Bit Origin, as Aethir's sales representative, aims to expand Aethir's market reach and has plans to acquire and deploy Aethir devices in Singapore and/or Malaysia. This strategic move is expected to enhance the Company's service offerings and drive significant growth for both companies. "We are excited to partner with Aethir, whose technology is truly transformative," said Jinghai Jiang, Chairman of the Board, CEO, and COO of Bit Origin Ltd. "This collaboration will significantly enhance our offerings while driving substantial growth and value for both companies."

09:06 EDT Sage Group annouces launch of Sage for Specialty Contractors - Sage announces the launch of Sage for Specialty Contractors, an end-to-end native-cloud construction suite that is built to handle the complexities specialty contractors face every day. Sage for Specialty Contractors enables contractors to handle every aspect of their business from preconstruction to closeout, and everything in between. It helps them save time, avoid error-prone work, improve communication with field teams, and make informed decisions with real-time data.

13:05 EDT HP Inc. appoints Parkhill as Chief Financial Officer - HP (HPQ) announced that Karen Parkhill will join the company as Chief Financial Officer on August 5, 2024. Tim Brown, who has been serving as interim Chief Financial Officer, will return to his role as the head of Print Finance. Parkhill, has spent the past 13 years serving as the Chief Financial Officer for well-established, publicly traded companies. Parkhill joins HP from Medtronic (MDT) where she served as Executive Vice President and Chief Financial Officer since 2016.

09:04 EDT Oramed announces $20M share repurchase plan - Oramed Pharmaceuticals announced that its Board of Directors has authorized a common stock repurchase plan allowing for the buy-back of up to $20M in maximum value of its common stock through open market purchases, privately-negotiated transactions, or otherwise in compliance with Rule 10b-18 under the Securities Exchange Act of 1934, as amended, over the next 12 months.

09:04 EDT Nexalin Technology announces 'positive' study data in MDD - Nexalin Technology announced positive results of a clinical study designed to evaluate the feasibility, safety, and efficacy of transcranial alternating current dynamic frequency stimulation as an add-on treatment for the symptoms of major depressive disorder, MDD, also known as clinical depression, a mental health condition that affects mood, behavior, appetite, and sleep. The study was designed as a 4-week, double-blind, randomized, sham-controlled trial, in which sixty-six participants were recruited and randomly assigned to receive 20 40-minute sessions of either active treatment using the Company's non-invasive Deep Intracranial Frequency Stimulation technology or sham stimulation. Significant differences were found in the reductions in the Hamilton Depression Rating Scale scores at week 4. Response rates at week 4 were significantly higher in the active tACS group than in the sham tACS group. In the active tACS group, a correlation between the mean change in alpha power and HAMD-17 scores at week 4 was found, and the mean change in alpha power was significantly greater for responders. No serious adverse events were observed in this trial.

09:02 EDT Synaptogenix announces FDA approved IND application for Bryostatin-1 - Synaptogenix announced that the FDA has authorized an Investigational New Drug, or IND, application for Bryostatin-1 as a potential treatment for multiple sclerosis, or MS. The fully-funded, open-label clinical trial will be held and managed at Cleveland Clinic Neurological Institute's Mellen Center for Multiple Sclerosis. The study will utilize state-of-the-art 7-tesla magnetic resonance imaging, or MRI, technology to identify biomarkers for evaluating Bryostatin-1's impact on the brain. Bryostatin-1 is a small molecule that works by activating protein kinase C, or PKC, enzymes required for maintaining synapse health and is involved in learning and memory. The therapy may also enhance anti-inflammatory efficacy to prevent degradation of the insulating sheath around nerve fibers. With a balance sheet including approximately $26.3M in cash as of March 31, the Company's Phase 1 MS trial is fully-funded. The Company maintains a relatively low cash burn rate and ample resources to support continued development of Bryostatin-1 for MS and other indications, as well as to pursue research on other innovative assets and/or the potential acquisitions of asset rights.

09:01 EDT AgriFORCE retains Barrett Moonet as Agricultural Technical Consultant - AgriFORCE Growing Systems has retained Barrett Mooney as an Agricultural Technical Consultant. Dr. Mooney served as the CEO and Chairman of the Board for a NYSE-listed aerospace and defense company where he led the company through several major acquisitions and the transition from private to publicly traded.

12:48 EDT Interactive Brokers considers options related to $48M loss on Berkshire anomaly - Interactive Brokers (IBKR) stated in a press relase: "On the morning of Monday, June 3, 2024, at approximately 9:50 am EDT, the price of Berkshire Hathaway Class A shares (BRK.A) suddenly plummeted in the space of a few seconds from approximately $622,000 per share to approximately $185 per share. This occurred as part of an unspecified technical issue at the New York Stock Exchange (ICE). This technical issue and dramatic price event led NYSE to promptly halt BRK A from trading. News of BRK A's anomalous price drop quickly spread across social media. Some of the clients of the various brokerage subsidiaries of Interactive Brokers Group, Inc., in an apparent attempt to take advantage of this 'opportunity,' submitted market buy orders during the trading halt, presumably expecting those orders to be filled at approximately $185/share when trading resumed. Without any further notice and without addressing a substantial order imbalance that developed during the halt, NYSE resumed trading of BRK A at approximately 11:35:54 am EDT at a price of $648,000. Over the next 98 seconds, the price of BRK A rose to as high as $741,971.39 per share. Many of the Company's clients that had placed market buy orders during the trading halt were filled at various prices during this run-up, including some who were filled at the peak price. The Company promptly filed a clearly erroneous execution petition with NYSE and certain other U.S. exchanges, seeking to bust the trades that had occurred at anomalously high prices during the disorderly market that followed the resumption of trading. NYSE did not respond to that petition until several hours later, after the close of regular trading hours. At approximately 6:30 pm EDT, NYSE informed the Company that it had determined, together with the other US stock exchanges, that it would decline to act with respect to IBLLC's CEE petition. That evening, the Company determined to take over a substantial portion of these trades as a customer accommodation. The Company also promptly filed claims for compensation with NYSE. On June 25, 2024, NYSE notified the Company that it had denied those claims in full. As a result, the Company has realized losses, including losses on certain hedge transactions, in the amount of approximately $48M. The Company is continuing to consider its options with respect to recovery of these amounts, including any claims at law it could assert against NYSE or related entities. The Company does not believe that these losses will have a material effect on its financial condition."

08:38 EDT Jaguar Health regains compliance with Nasdaq's bid price requirement - Jaguar Health received formal notice from The Nasdaq Stock Market that Jaguar has regained compliance with Nasdaq's minimum bid price requirement.

08:38 EDT Taysha Gene Therapies falls 12% to $2.16 after filing to sell $75M shares

08:37 EDT Energous announces new partnerships with Annukin, Ecobyte, Peak Technologies - Energous Corporation announced new partnerships with Annukin, Ecobyte, and Peak Technologies to help accelerate adoption of the company's solutions worldwide. "Annukin, Ecobyte, and Peak Technologies joining the Energous partner ecosystem represents a significant step forward in our ability to provide global solutions that address the growing need for cost effective, reliable, and consistent power for internet-connected devices and IoT applications in supply chain, retail, and healthcare settings," said Mallorie Burak, Interim Principal Executive Officer and CFO of Energous. "Joining forces with experienced partners accelerates access to the Energous solutions that provide the fundamental building block - wireless power - to customers looking to optimize and build the warehouses of tomorrow and energize a new generation of battery-free IoT-enabled devices, from retail sensors and asset trackers to air quality monitors, motion detectors, and more."

08:35 EDT Webuy launches Sing Select gift series - Webuy Global announced the launch of its Sing Select gift series, a new line of high-quality, thoughtfully curated gift sets designed to celebrate the rich and diverse culture of Singapore. The series was officially launched in May 2024 with the Plum Wine Gift Set as the first proprietary product in the series. Consumer demand for the Plum Wine Gift Set has exceeded expectations, with more than 700 sets sold in a single day. Building on the initial success of the Plum Wine Gift Set, Webuy is expanding the Sing Select gift series to include a variety of other high-quality Company-designed and wholly owned branded products. Upcoming launches will feature a range of gift sets such as healthy nuts, premium teas, and gourmet coffees.

12:34 EDT Cellebrite announces availability of Endpoint Inspector SaaS on AWS Marketplace - Cellebrite (CLBT) announced that its Endpoint Inspector SaaS, the Company's real-time data access, collection and analysis solution, is now available on Amazon Web Services Marketplace (AMZN), Endpoint Inspector SaaS empowers private sector corporate investigators and eDiscovery practitioners to securely collect and analyze data in real-time from a wide range of remote devices and computers. By leveraging the AWS cloud infrastructure, businesses can manage their targeted data collection activities seamlessly, allowing for faster extraction of critical information and ultimately deeper insights into corporate digital investigations and e-discovery.

08:34 EDT Cibus expands intellectual property coverage for plant gene editing, traits - Cibus announced that it has expanded its intellectual property coverage for 10 gene editing and trait families. This intellectual property expansion over the last 6 months covers several areas including gene editing, productivity traits and quality traits, like high fiber wheat, strengthening the Company's patent coverage in geographies including, but not limited to, Europe, EPO, Asia, Latin America, Canada, and the United States. Greg Gocal, PhD, Co-Founder, Executive Vice President and Chief Scientific Officer at Cibus, commented, "The development of our intellectual property is foundational to our strategy and demonstrates our ability to edit complex traits across multiple crops. We are pleased with the recognition of the patent offices in many countries, who through their decisions have validated our know-how and ability to develop gene edited traits.."

08:33 EDT Aclarion announces initial payer coverage of Nociscan by AXA in London, UK - Aclarion announced their initial payer coverage of Nociscan by AXA in London, UK in conjunction with The London Clinic, one of the UK's largest and most renowned independent hospitals. AXA is a leading provider of private medical insurance in the UK. "Securing first payer coverage is the most significant milestone Aclarion has achieved to date," said Brent Ness, CEO Aclarion. "This is a monumental step in launching widescale commercialization efforts at Aclarion. Nothing becomes standard of care in healthcare without reimbursement and we have now validated our strategy in one of the largest, most sophisticated healthcare markets in the world. We anticipate additional coverage decisions in the weeks to come and will be filling reimbursed markets with sales teams trained to drive adoption. We are very committed to serving the needs of the patients covered by this AXA payer decision. Evidence to date demonstrates that when Nociscan is incorporated into the treatment plan, outcomes significantly improve. This evidence and our physician support is why other payers will be following AXA's example."

08:32 EDT RenovoRx announces UNMC is enrolling patients with LAPC for Phase III trial - RenovoRx announced that the University of Nebraska Medical Center, UNMC, is now enrolling patients with Locally Advanced Pancreatic Cancer, LAPC, in the Company's ongoing pivotal Phase III TIGeR-PaC clinical trial. The TIGeR-PaC study is using RenovoRx's patented TAMP therapy platform to evaluate its RenovoGem investigational drug-device combination product. RenovoGem utilizes pressure-mediated delivery of chemotherapy across the arterial wall to bathe tumor tissue. The study is comparing treatment with TAMP to the current standard-of-care.

08:31 EDT Dana appoints Lisa Amend as Chief Human Resources Officer - Dana Incorporated announced the appointment of Dana veteran Lisa Amend as Senior Vice President and Chief Human Resources Officer. Amend brings to this role more than 20 years of experience as a labor and employment attorney supporting human resources in all areas, including litigation and dispute management, labor relations, employee benefits, and executive compensation. She will have responsibility for the company's human resources strategy and processes, including talent lifecycle and acquisition; talent management and development; diversity, equity, and inclusion; employee engagement; and workforce planning. Amend has been with Dana for more than 12 years, beginning in 1998, where she served as a member of the Law Department until 2006. She rejoined Dana in 2020 as Senior Legal Counsel and served as a member of the Office of Business Conduct before being named Vice President, Assistant General Counsel, and Assistant Secretary in 2023. Before her time with Dana, Amend served as managing counsel for Marathon Petroleum Corporation and worked in private practice at the law firm of Taft, Stettinius & Hollister.

08:25 EDT Politan outlines need for 'truly independent board' at Masimo - Politan Capital Management , an 8.9% shareholder of Masimo sent a letter to the company's shareholders outlining why a majority of truly independent directors are urgently needed in the Masimo boardroom. Politan also released a detailed investor presentation making the case for change and why independent nominees - Darlene Solomon, former Chief Technology Officer of Agilent, and Bill Jellison, former Chief Financial Officer of Stryker - would bring critically needed expertise to Masimo's Board of Directors. The full presentation can be found here. Additional information can be found on www.AdvanceMasimo.com. "Politan owns 9% of Masimo - an approximately $600M investment that makes us one of the Company's largest shareholders. We invested in Masimo over two years ago because we believe in the Company's tremendous promise. However, it has become clear that to protect shareholder value, let alone realize Masimo's potential, the Company needs a majority of truly independent directors. This is why we have nominated to the Board Darlene Solomon, former Chief Technology Officer of Agilent, and Bill Jellison, former Chief Financial Officer of Stryker - two unquestionably independent nominees who bring crucial expertise needed in Masimo's boardroom. We have made numerous efforts to avoid another proxy contest. Each of our settlement proposals has offered Mr. Kiani the opportunity to remain on the Board. Our offers still stand. Masimo has proposed to seat both Dr. Solomon and Mr. Jellison, but only if we agreed to a separation transaction on the terms that Mr. Kiani had sought earlier this year..."

08:20 EDT Team Mogo Esports advance to finals of Krafton Battle Grounds Mobile India - The company said, "Team Mogo Esports is thrilled to announce that we have advanced to the finals of the highly anticipated Krafton Battle Grounds Mobile India Series 2024. The prestigious event will take place in Hyderabad from June 28th to June 30th, 2024. The road so far has been nothing short of relentless determination, strategy, skillset-mastery, and competition Te.am Mogo Esports has emerged as a pole contender in this year's series. Our advancement to the finals is a message of what our team is capable off. The unyielding support from our fans and the entire esports community keeps our team going and aiming for the title."

08:17 EDT Stratasys enrolls first patient in orthopedic oncology 3D printed model study - Stratasys and Ricoh announced the enrollment of the first patient in a clinical study aimed to evaluate the use of 3D printed models for orthopedic oncology. The study will assess the efficacy of patient-specific 3D printed anatomical models for preoperative planning and tumor excision in comparison to the current standard of care, which relies solely on CT or MRI imaging. The joint research aims to demonstrate potential improvements in surgical outcomes, including reduced blood loss, shorter operating time including time under anesthesia, and decreased risk of procedural complications. To do this, clinical outcomes will be compared between an experimental group in which tumors are excised using 3D printed models alongside imaging for planning, and an active comparator group in which tumor excision will be prepped solely with imaging.

08:16 EDT Ricoh USA and Stratasys enroll first patient in clinical study with 3D models - Ricoh USA and Stratasys announced the enrollment of the first patient in a groundbreaking clinical study aimed to evaluate the use of 3D printed models for orthopedic oncology. The study will assess the efficacy of patient-specific 3D printed anatomical models for preoperative planning and tumor excision in comparison to the current standard of care, which relies solely on CT or MRI imaging. The joint research aims to demonstrate potential improvements in surgical outcomes, including reduced blood loss, shorter operating time including time under anesthesia, and decreased risk of procedural complications. To do this, clinical outcomes will be compared between an experimental group in which tumors are excised using 3D printed models alongside imaging for planning, and an active comparator group in which tumor excision will be prepped solely with imaging. The benefits of 3D printed models in preoperative planning are severalfold and positively impact both medical practitioners and patients alike. Doctors and surgeons benefit from improved and more informed presurgical planning and practicing prior to operations, making complex procedures more efficient, economical and faster.

08:15 EDT Stream Hatchet renews, expands relationship with Riot Games - Stream Hatchet has renewed its relationship with Riot Games. Stream Hatchet has been providing Riot Games with SaaS-based analytics solutions for five years and recently expanded its scope with Riot Games with additional influencer marketing capabilities provided by Sideqik, also a GameSquare company.

08:12 EDT Sempra Energy and Aramco announce sale and purchase agreement for LNG - Aramco and Sempra announce that their respective subsidiaries have executed a non-binding Heads of Agreement, or HoA, for a 20-year sale and purchase agreement, or SPA, for liquefied natural gas, or LNG, offtake of 5.0 million tonnes per annum, or Mtpa, from the Port Arthur LNG Phase 2 expansion project. The HoA further contemplates Aramco's 25% participation in the project-level equity of Phase 2. The parties expect to execute a binding LNG SPA and definitive equity agreements with terms substantially equivalent to those in the HoA, with the SPA and equity agreements subject to a number of conditions.

08:11 EDT Vir gets FDA clearance, fast track designation for tobevibart and elebsiran - Vir Biotechnology announced that the FDA has cleared its investigational new drug, or IND, application and granted Fast Track designation for the combination of tobevibart and elebsiran for the treatment of chronic hepatitis delta infection. Tobevibart, an investigational monoclonal antibody, and elebsiran, an investigational small interfering ribonucleic acid, are currently being evaluated in the company's Phase 2 SOLSTICE hepatitis delta clinical trial, with complete 24-week treatment data on track to be reported in the fourth quarter.

08:09 EDT iCAD to highlight research on potential of its ProFound AI Risk algorithm - iCAD announced it will highlight new research demonstrating the efficacy of its ProFound AI Risk algorithm in breast cancer risk assessment compared to traditional models at the upcoming Society for Imaging Informatics in Medicine, SIIM, Annual Meeting. The company will also highlight its recently launched ProFound Cloud, an advanced software-as-a-service, SaaS, platform that offers medical providers a cost-effective, secure, and scalable solution for accessing and deploying the latest ProFound Breast Health Suite of AI solutions. "Dr. Traill's latest research is a significant step forward in the application of iCAD's ProFound AI Risk for breast cancer risk assessment. The ability to identify women with a higher likelihood of breast cancer by analyzing changes in AI-derived risk score between a woman's prior and current mammogram will facilitate earlier intervention and improve outcomes," said Dana Brown, president and CEO of iCAD.

08:08 EDT Bluejay Diagnostics announces results from preliminary analysis of SYMON-I - Bluejay Diagnostics announced results from the primary analysis of SYMON-I, a multicenter pilot clinical study investigating the role of interleukin-6 in patients diagnosed with sepsis and septic shock. This prospective study assessed the utility of IL-6 upon initial presentation to the intensive care unit, ICU. The primary analysis of the SYMON-I study highlighted that IL-6 levels within 24 hours of sepsis or septic shock diagnosis and admission to the ICU may predict patient mortality out to 28 days. These findings will be validated in the SYMON-II pivotal study. Furthermore, a secondary outcome of the SYMON-I study showed that IL-6 levels within 24 hours of sepsis or septic shock diagnosis and admission to the ICU is a predictor of patient mortality during their hospitalization. Bluejay Diagnostics is planning to initiate the SYMON-II pivotal clinical study in Q3 2024. If the results are positive, the Company intends to use SYMON-II as support in a 510(k) application to the FDA in 2025 for the following intended use: Symphony IL-6 is intended for use to determine the IL-6 concentration as an aid in assessing the cumulative 28-day risk of all-cause mortality in conjunction with other laboratory findings and clinical assessments for patients diagnosed with sepsis or septic shock in the ICU.

12:07 EDT Crowdstrike exceeds $1B in sales with CDW - CrowdStrike ( CRWD) announced it has surpassed $1B in total sales over the lifetime of its partnership with CDW (CDW). CrowdStrike has also achieved CDW's Diamond Level Partner Status, joining just a handful of select technology giants who are key to CDW's $20B business. "The milestones of both $1 billion in sales and Diamond Level Partner Status signify the incredible impact CrowdStrike and CDW have in bringing industry-leading security to thousands of customers. Together, we've found the recipe for success, modernizing security operations with AI, consolidating legacy products and increasing ROI with the Falcon platform," said Daniel Bernard, chief business officer at CrowdStrike. "From our early days, CDW has led with CrowdStrike, bringing our cutting-edge technology to a multitude of organizations. We're thrilled to achieve such significant success with our long-standing partner CDW, and we look forward to furthering our commitment to stopping breaches together."

08:06 EDT Ocean Power reach agreement for delivery of multiple WAM-Vs to U.S. government - Ocean Power Technologies announced it has reached an agreement in principle on a sole source contract award for multiple WAM-Vs for delivery to a Department of the US Government. The final contract award will be a Firm-Fixed-Price purchase order on a noncompetitive basis. Revenue will be recognized ratably over the course of the contract with an expected near-term delivery date. Due to the sensitive nature of this relationship, terms have not been disclosed. Philipp Stratmann, CEO and President of OPT, expressed his enthusiasm about this revenue generating contract, stating, "We believe this agreement is further proof that our systems form an important part of building out the future of ocean security. Using small Unmanned Surface Vehicles, like our WAM-V, is a cost-efficient force multiplier for the US Government and other offshore operators. The dual use nature of our technologies enables us to provide systems to a broad set of customers."

08:06 EDT BAIYU announces MoU with industry experts to explore new energy vehicle - BAIYU Holdings announced that on May 20, the Company entered into a memorandum of understanding, or MoU, with certain industry experts to explore new energy vehicle, or NEV, projects and international market ventures. This strategic move reflects BAIYU's ambition to expand into the rapidly growing and promising global NEV market. According to the MoU, BAIYU and the Partners intend to conduct the new business through Electra New Energy Vehicle, a U.S.-registered company based in Los Angeles specializing in the NEV sector. BAIYU and the Partners anticipate holding 60% and 40% equity interests in ENEV, respectively. Both parties plan to collaborate to establish a prominent NEV brand. BAIYU expects to potentially invest a total of $3M in ENEV as operational capital over the next three years. Under the MoU, BAIYU intends to oversee the daily operations and management of ENEV, encompassing procurement, manufacturing, supply chain, marketing, and financing for NEV prototypes, spare parts, charging piles, and energy storage equipment in China. The Partners aim to handle market development, order acquisition for NEVs, charging piles, and energy storage equipment in international markets, and secure overseas financing.

08:04 EDT Chipotle shares to begin trading on a post-split basis on June 26 - Chipotle Mexican Grill announced that its 50-for-1 stock split was effective after market close on June 25 and its shares will begin trading on a post-split basis on June 26. After market close yesterday, shareholders of record as of June 18 received 49 additional shares for each share held. To commemorate this special event and in recognition of the company's strong performance, Chipotle will offer a special one-time equity grant to all restaurant general managers as well as crew members with more than 20 years of service.

08:04 EDT SunOpta completes $26M expansion at Modesto, Calif. facility - SunOpta announced it has completed a $26M expansion at its Modesto, Calif. facility. "As the second largest project in the company's history, the expansion allows SunOpta to increase the amount of oatmilk produced annually by more than 60%, meeting ongoing customer demand and demonstrating SunOpta's commitment to plant-based beverage production. Commercially launched in May, SunOpta's Modesto oat extraction production line uses proprietary enzymatic processes to break down whole oats into a liquid oatbase that will then be used to make oatmilk and other products such as plant-based yogurt and ice cream. The new expansion has created 17 new jobs in the community. SunOpta supplies liquid and dried oatbase as an ingredient to companies large and small, manufactures oatmilk for leading brands and food service operators throughout the country and produces private label oat-based products for many top national retailers." "Through this significant investment in Modesto to produce more oatbase, we're well positioned to meet the increasing market demand for plant-based milk and other oat-based products," said Brian Kocher, CEO of SunOpta. "We are also pleased to bring 17 new positions to our Modesto team and continue making a positive impact in the communities in which we work and live."

08:03 EDT Genasys awarded LRAD systems order from Damen Schelde Naval Shipbuilding - Genasys announced an LRAD 950NXT systems order from Damen Schelde Naval Shipbuilding for the German Navy's new F-126 frigates, the largest shipbuilding project in the history of the German Navy. Damen will outfit four frigates with multiple LRAD 950NXT systems, with an option to outfit two additional frigates. The first shipment is scheduled this September with further shipments in fiscal years 2025 and 2026

08:01 EDT BrainStorm reached alignment with FDA on Phase 3b clinical trial for NurOwn - BrainStorm Cell Therapeutics announced it has reached alignment with the FDA on the Chemistry, Manufacturing, and Controls, or CMC, aspects of Brainstorm's Phase 3b clinical trial for NurOwn, its investigational therapy for amyotrophic lateral sclerosis, or ALS. This Type C meeting builds upon the positive momentum established in April 2024, when the FDA granted BrainStorm a Special Protocol Assessment, or SPA, agreement for its NurOwn Phase 3b trial. The SPA agreement provided clarity on the design and endpoints of the trial, significantly de-risking the regulatory aspects of the program.

07:50 EDT Ecora Resources announces director/PDMR shareholding - Ecora Resources announces that on 25 June 2024 the Company transferred 185,809 ordinary shares of 2 pence each in the Company out of treasury, to satisfy exercises of options by a number of employees, including Marc Bishop Lafleche, CEO and Kevin Flynn, CFO Mr. Bishop Lafleche and Mr. Flynn exercised 49,903 and 79,565 nil cost option awards granted under the Company's Long Term Inventive Plan on 27 May 2021, respectively. Subsequently, Mr. Bishop Lafleche and Mr. Flynn sold 23,549 and 37,546 Shares, respectively, at an average approximate price of GBP 0.746 per Share, to satisfy income tax associated with the Awards. Following the above Transfer, the Company's issued capital consisted of 261,732,553 Shares, of which 13,134,660 Shares were held in treasury.

07:47 EDT Agile Therapeutics to be acquired by Insud Pharma for $1.52 per share in cash - Agile Therapeutics has entered into a definitive merger agreement with Insud Pharma, pursuant to which Insud, through its US subsidiary, Exeltis Project, will acquire Agile for $1.52 per share in cash net of assumed liabilities and estimated transaction costs for an approximate total enterprise value of $45M. On June 25, 2024, Agile also entered into a cash-out acknowledgment and cancellation agreement with the holders of not less than ninety-five percent of the Company's outstanding common stock warrants, also conditioned on closing of the merger. As a condition to entering into the Merger Agreement, Agile has also entered into a third amendment of its Manufacturing and Commercialization Agreement with Corium Innovations on commercial terms reasonably acceptable to Insud and conditioned on the closing of the merger. As part of the merger consideration for Agile, Insud has agreed to make available a line of credit of up to $8,000,000, secured by the Company's intellectual property. The initial amount to be advanced under the Bridge Loan will be used primarily to pay for the purchase of inventory. The Board of Directors of Agile has unanimously approved the transaction. The transaction is expected to close in the third quarter of 2024, subject to completion of Agile's obligations to Corium under Amendment No. 3 and other customary closing conditions, including approval by Agile's stockholders. Upon completion of the transaction, Agile will no longer be listed on any public market.

07:39 EDT Mattr Corp. announces renewal of normal course issuer bid - Mattr announced that the Toronto Stock Exchange has approved the Company's notice of intention to renew its normal course issuer bid for common shares of the Company. Pursuant to the NCIB, the Company may purchase for cancellation up to 4,982,824 Common Shares, representing approximately 10% of the Company's public float as at June 14, 2024. As at the date hereof, the Company has 66,372,274 Common Shares issued and outstanding. The NCIB will commence on June 28, 2024 and terminate one year after its commencement, or earlier if the maximum is reached or the NCIB is terminated at the option of the Company. The Company believes that using the NCIB to return capital to its shareholders will increase shareholder value and further the returns of the Company. All purchases pursuant to the NCIB will be made through the facilities of the TSX, or such other permitted means, at prevailing market prices or as otherwise permitted. The NCIB will be funded using existing cash resources and any Common Shares repurchased by the Company under the NCIB will be cancelled. Other than purchases made under a block purchase exemption pursuant to the rules and policies of the TSX, daily purchases on the TSX pursuant to the NCIB will be limited to 30,099 Common Shares, which represents approximately 25% of the average daily trading volume of 120,397 Common Shares of the Company for the most recently completed six calendar months preceding May 31, 2024.

07:36 EDT Victory Square portfolio company Hydreight provides corporate update - Victory Square Technologies shared that its portfolio company - Hydreight Technologies provided a corporate update reflecting its significant organic growth, increased patient visits, and strong revenue growth. Shane Madden, CEO of Hydreight commented, "I am incredibly pleased with the significant growth the Company has been able to achieve. We continue to focus on our mission of becoming the leading mobile clinical network across North America. Currently our platform services 50 states in the US, which is a significant milestone for us considering the complex and different healthcare legislation across all states. Our investment in our technology and infrastructure in 2023 lead to become a fully automated, fully integrated, turnkey solution for mobile medicine across the board. This has already been paying off by signing more types of businesses. Our focus in 2024 is to continue growing the revenue, becoming a profitable company and introducing our story to more potential shareholders." Financial and Revenue Growth: Hydreight Reported Record Topline Revenue of $4.87M in Q1-2024. Here is a summary of Q1, 2024 financial highlights: Q1, 2024 GAAP revenue was $3.38 million an increase of 44% compared to Q1, 2023. Q1, 2024 topline record revenue of $4.87 million, an increase of 33% compared to Q1, 2023. Q1, 2024 gross margin of $1.23 million compared to $1.04 million in Q1, 2023. The Company has approximately 117 white-label locations nationwide, with new locations opening every month. The company has never raised or borrowed any additional capital since the original RTO in December 2022. Adjusted EBITDA has improved and is projecting a path to profitability.

07:35 EDT Enovix signs Memorandum of Understanding with Elentec - Enovix Corporation announced it has signed a Memorandum of Understanding, MOU, with Elentec Co. The agreement provides a framework for a long-term business relationship between the two companies and enables Enovix to lock in a globally trusted battery pack manufacturing partner to support its growth with target customers worldwide. The MOU allows Enovix to fast track and utilize Elentec's battery pack design and high-volume manufacturing capability, while setting up the framework for definitive long-term supply and/or joint manufacturing agreements leveraging Elentec's footprint. Contingent on continued success in both technical and business negotiations, the companies intend to enter a strategic partnership, and collaborate in the incorporation and custom development of Enovix battery cells into multiple battery packs for consumer, industrial, and military applications to support both Enovix and Elentec's key customers.

07:33 EDT Greenwich LifeSciences set to join Russell 2000 Index - Greenwich LifeSciences is set to join the Russell 2000 and Russell 3000 Indexes at the conclusion of the Russell indexes annual reconstitution, effective after the US markets open on July 1, 2024, according to a list of additions updated as of June 21, 2024.

07:33 EDT Altimmune announces passing of CFO Richard Eisenstadt - Altimmune announced that Richard Eisenstadt, the Company's CFO, passed away unexpectedly on Monday, June 24, 2024. Mr. Eisenstadt's duties have been assumed and are being performed by Altimmune's finance and accounting team until his replacement is named. The company has initiated a search for his replacement.

07:24 EDT PowerBand Solutions provides bi-weekly MCTO status update - PowerBand Solutions is providing a bi-weekly status update in accordance with the National Policy 12-203 - Management Cease Trade Orders. As previously announced on April 16, 2024, the Company applied for the MCTO due to a delay in the filing of the audited consolidated financial statements for the year ended December 31, 2023, annual management's discussion and analysis for the same period and management certifications of annual filings. The MCTO was granted by the Ontario Securities Commission on April 30, 2024. Rhe Company completed the Filings on June 14, 2024, and the unaudited interim financial statements, related management's discussion and analysis and CEO and CFO certifications for the period ended March 31, 2024, was filed on June 24, 2024, and copies are available under the Company's profile at SEDAR+. The Company anticipates that the MCTO will be lifted on June 26, 2024. The MCTO restricts the Company's CEO and CFO from trading in the Company's securities but does not affect the ability of other shareholders, including the public, to trade in securities of the Company.

07:22 EDT Verizon announces customer-first programs, benefits - Verizon is announcing new programs and benefits that continue to give customers more choices and flexibility, and advance the momentum in the business. Verizon is also refreshing its brand, bringing forward the energy and vibrancy of how people live, work and play, powered by Verizon. The refreshed branding and creative formats will be rolling out across the company's consumer, business and network footprints. Verizon is introducing new choices and flexibility for Home Internet customers with the launch of myHome, an extension of its popular myPlan mobile offering, and implementing an always-on guaranteed phone trade-in program for new and existing mobility customers. The company also unveiled Verizon Access, a new platform for all customers that provides exclusive access to the most sought-after events and experiences, including NFL games, music festivals, concerts and more. Verizon Business is also launching an industry-first smartphone management solution that offers business customers more choices and peace of mind for managing their company's smartphones.

07:09 EDT Skeena Resources to host webcast on Eskay financing package - Skeena Resources has secured a financing package totaling $750M with Orion Resource Partners for the development of the Eskay Creek Gold-Silver Project, as per the Company's news release dated June 25, 2024. The Company will be hosting a webcast to provide investors and stakeholders with a comprehensive understanding of this development and the strategic rationale behind this deal. During the webcast, Walter Coles, Executive Chairman, Randy Reichert, President & CEO and Andrew MacRitchie, CFO alongside other members of the Management team, will provide insights into how this financing package will enhance the strategic direction of the Company.

07:08 EDT Herbalife expands board of directors - Herbalife welcomed e-commerce and media technology executive Perkins Miller to its board of directors. Miller's appointment as an independent director is effective June 26. Miller is the CEO of Fandom.

07:07 EDT General Mills increases quarterly dividend 2% to 60c per share - The General Mills board of directors declared a quarterly dividend of 60c per share, payable August 1 to shareholders of record July 10. This represents a 2% increase from the previous quarterly rate of 59c per share.

07:07 EDT Tiziana Life to dose first patient with moderate Alzheimer's with foralumab - Tiziana Life Sciences announced that the U.S. Food and Drug Administration, FDA, has allowed intranasal foralumab to be used under an Expanded Access, EA, IND in its first patient with moderate Alzheimer's disease. Expanded access IND's provide a pathway for patients to gain access to investigational drugs, biologics, and medical devices used to diagnose, monitor, or treat patients with serious diseases or conditions for which there are no comparable or satisfactory therapy options available outside of clinical trials. Gabriele Cerrone, Chairman, acting CEO and founder of Tiziana Life Sciences commented, "In addition to our previously announced IND clearance of the Phase 2a early symptomatic Alzheimer's Disease study, this additional FDA clearance allows Tiziana to also study intranasal foralumab in patients with moderate Alzheimer's Disease who do not qualify for approved therapies."

07:05 EDT GCM Grosvenor commits $50M to OlivePoint's latest investment fund - OlivePoint, a private real estate investor announced that GCM Grosvenor an asset management solutions provider has committed, on behalf of various U.S. Pension Plans, $50M to OlivePoint's latest investment fund. The investment is being made through GCM Grosvenor's Real Estate platform, which provides catalytic seed capital to emerging real estate investors to help launch and scale their investment businesses... "We are excited to strategically partner with the OlivePoint team to invest in opportunistic real estate assets across the U.S. Over the course of their careers, Adrian, John, and Ricardo have demonstrated the ability to thoughtfully manage risk and protect their investors' capital while identifying unique opportunities. As such, we believe OlivePoint can potentially create meaningful alpha for our investors in today's challenging market environment."Adrian Bejarano, John Bruno, and Ricardo Goldberg, Co-Founders and Managing Partners of OlivePoint, added, "We are pleased to welcome GCM Grosvenor as a strategic investor, and we are grateful for their support and the confidence they are placing in us to invest on behalf of their institutional clients. This investment is a powerful endorsement of our investment strategy and our proven, experienced team. We are looking forward to a long and successful partnership with the GCM Grosvenor team."

07:05 EDT Steakholder Foods CEO says focus remains on securing commercial deals - Steakholder Foods shared a letter from the CEO, Arik Kaufman, which read in part, "I am excited to share the significant strides we have made in the first half of this year, particularly in our efforts to drive commercial success to be able to create our first revenue streams. Our recent strategic partnerships and technological advancements underscore our commitment to become one of the leading players in the alternative protein sector. On the technology front, our advancements in 3D printing technology remain at the forefront of our progress. The Drop Location in Space technology, a cornerstone of our seafood replication process, allows us to create textures that mirror the delicate structure of real seafood. Similarly, our Fused Paste Layering technology plays a crucial role in replicating meat's fibrous texture, ensuring our plant-based meats rival their animal-based counterparts. Our SHMEAT and SHFISH premixes have also evolved, offering a wide range of plant-based alternatives that cater to diverse culinary tastes and dietary preferences. From the savory SHMEAT(TM) Beef Steak blend to the delicate SHFISH White Fish blend, our products are crafted to provide an authentic and enjoyable eating experience. Our journey toward commercialization reached a significant milestone this past May, entering a royalties and raw materials supply agreement and establishing a near term future concrete revenue stream. This agreement with Wyler Farm, a leader in alternative protein production, marked our initial foray into commercial partnerships, validating the market potential of our technology and setting the stage for future growth. The terms of the deal involved Wyler Farm acquiring our state-of-the-art MX200 meat printer, along with a SHMEAT premix for plant-based meat production. Wyler Farms will manufacturer alternative proteins on a commercial scale using our premixes and know-how, in return for payment of royalties from sales. Production of the new plant-based meat products is tentatively expected to begin in H2 2024, followed by commercial revenues. We continue our negotiations with Wyler Farm and hope to reach a second-stage follow-on agreement, in which Wyler Farm would produce plant-based 3D-printed meat products utilizing our proprietary 3D printing technology and premix blends, including producing our flagship Printed Beef Steak product. Also in May, we announced a partnership agreement with the Industrial Technology Research Institute, a Taiwan-based world-leading applied technology research institute. The purpose of the partnership is to develop and commercialize a wide range of food products utilizing our proprietary 3D printing technology and plant-based premixes tailored specifically for Taiwanese cuisine. To accelerate expansion across Taiwan, the partnership will focus on commercializing Steakholder Foods' products through collaborations with leading food companies in Taiwan. A key part of this strategy will involve the sale of our commercial-scale 3D printer and premixes to commercial partners. Lastly, in June we announced the signing of a MOU to establish a strategic partnership with Sherry Herring, a highly-recognized gourmet fish delicacies brand. The partnership plans to unveil a new line of vegan fish salads developed with the company's proprietary SHFISH premix blends. The collaboration marks another step forward in advancing our commercialization strategy, leveraging Sherry Herring's regional expertise and brand recognition to expand our geographic footprint and customer base, and further bolstering our growing product portfolio. Capitalizing on Sherry Herring's well-established distribution network spanning delicatessens and restaurants, this new vegan fish salad line will roll out to Sherry Herring's current channels as well as new locations. Through the integration of SHFISH premix blends, we are aiming to redefine the seafood experience by offering plant-based alternatives that mimic the taste, texture, and nutritional profile of traditional fish salads, while providing a more sustainable and environmentally-friendly option. Utilizing innovative ingredients and culinary expertise, this collaboration seeks to cater to the rising consumer demand for sustainable and delicious plant-based options. Looking ahead to the back half of this year, our focus remains on securing commercial deals, expanding our market reach, and launching more product applications. We are excited about the future possibilities and confident in our continued success as we lead the way in alternative meat and fish production. The strategic partnerships and technological advancements we have achieved lay a solid foundation for our future growth and commercialization efforts."

07:02 EDT Hamilton Lane announces investment in Daphne Technologies - Hamilton Lane announced a partnership with, and investment in, Daphne Technologies, a platform facilitating distribution of alternative assets and increased efficiency of the fundraising process. As part of this partnership, Daphne has integrated with Cobalt - Hamilton Lane's proprietary private markets data, analytics, forecasting, and diligence platform. Daphne enables straight through data processing by which alternative asset managers can directly transmit fund information into Cobalt, greatly simplifying what has traditionally been a manual and painstaking process for both asset managers and their investors and channel partners. Daphne enables a direct digital connection between asset managers and their investors and channel partners.

06:56 EDT Southwest now sees Q2 RASM down 4%-4.5% vs. previous view down 1.5%-3.5% - The reduction in the company's RASM expectations was driven primarily by complexities in adapting its revenue management to current booking patterns in this dynamic environment. Despite lowered expectations, the company continues to expect an all-time quarterly record for operating revenue in second quarter 2024. Still sees Q2 ASMs up 8%-9%, and CASM-X up 6.5%-7.5% y/y.

06:34 EDT Babcock & Wilcox unit awarded more than $18M in contracts - Babcock & Wilcox announced that its B&W Environmental business segment has recently been awarded more than $18M in contracts to design and supply wet and dry electrostatic precipitator rebuilds for particulate emissions control in utility and industrial facilities in the United States and Europe.

10:34 EDT CGI Inc., Exxon Mobil renew payment and loyalty services partnership - CGI Inc. (GIB) announced the renewal of its partnership with ExxonMobil (XOM) for payment and loyalty services across Europe and the Asia Pacific region. CGI will further enhance customization options for ExxonMobil and its customers through its card payment solution, CGI PayPartner360.

06:33 EDT Transocean announces $188M Ultra-Deepwater drillship contract extension - Transocean announced a 365-day contract extension for the Deepwater Asgard with an independent operator in the U.S. Gulf of Mexico. The program is expected to commence in direct continuation of the rig's current program and is estimated to contribute approximately $188M in backlog, including additional services.

06:31 EDT Terran Orbital, Hanwha Systems sign Memorandum of Understanding - Terran Orbital announced the signing of a Memorandum of Understanding with Hanwha Systems. This MOU solidifies their strategic partnership, marking a significant milestone in their collaborative efforts to develop state-of-the-art solar and satellite solutions through Hanwha Systems and its subsidiary, Flexell Space. This strategic partnership aims to bolster the defense capabilities of both the United States and South Korea by providing cutting-edge solutions to the warfighter and establishing a robust supply base. As part of this collaboration, Terran Orbital and Hanwha Systems will work together on satellite manufacturing, including solar cells, and cooperate in the defense industry in both the US and South Korea. This strategic move will enable both companies to co-create joint solutions tailored for government bids, thereby advancing their mission objectives.

06:24 EDT MNC Capital raises all-cash offer to acquire Vista Outdoor to $42 per share - MNC Capital Partners announced it has increased its all-cash offer to acquire Vista Outdoor to $42.00 per share, or approximately $3.2B. The revised proposal represents a premium of 55% to the VWAP from when Vista's transaction with the Czechoslovak Group was announced on October 16, 2023 to the last closing price before MNC's initial offer on February 19, 2024. The revised offer is also an over 40% premium to the last closing price prior to MNC's initial offer. When MNC made its initial bid in mid-February, Vista's shares were trading below $30 - at that time, the market reflected the acquisition of Kinetic by CSG. Yesterday, Vista shares closed at $33.78 - the shares would have closed significantly lower without the expectation that MNC would be continuing to pursue the acquisition of Vista. MNC's revised proposal represents a premium of almost 25% to yesterday's closing price. Given MNC's belief that its acquisition of Vista is in the best interests of shareholders, employees and national security, MNC decided to make one final effort for such acquisition by increasing its June 6, 2024 proposal from $39.50 per share all cash to $42.00 per share all cash. MNC said that it cannot see any possible basis or reason to further raise it. MNC's revised proposal is all cash, has no regulatory issues and is not subject to any financing conditions. MNC holds secured debt and equity commitments more than sufficient to close the transaction and stands ready to provide those to Vista. MNC expects that the Vista Board will move forward expeditiously to sign a merger agreement on the terms proposed. MNC believes a definitive agreement can be executed in a matter of days.

06:17 EDT AstraZeneca says Tagrisso with addition of chemo approved in China for NSCLC - AstraZeneca's Tagrisso with the addition of pemetrexed and platinum-based chemotherapy has been approved in China for the first-line treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor-mutated non-small cell lung cancer, or NSCLC, whose tumours have exon 19 deletions or exon 21 mutations, the company announced.

06:06 EDT Vizsla Silver reports results from drill holes targeting Copala resource area - Vizsla Silver reports results from five new drill holes targeting the Copala resource area at its 100%-owned, flagship Panuco silver-gold project located in Mexico. The reported drilling, designed to infill near-surface Indicated Mineral Resources, continues to confirm high-grade continuity throughout Copala and reveals how rich the mineralizing hydrothermal system involved in initial vein formation was. Highlights: CS-24-356 returned 8,817 grams per tonne silver equivalent (AgEq) over 4.20 metres true width; Including 55,769 g/t AgEq over 0.64 mTW; CS-24-362 returned 1,103 g/t AgEq over 10.50 mTW; Including 4,881 g/t AgEq over 1.47 mTW; And, 1,379 g/t AgEq over 0.91 m TW. "Today's results represent some of the highest-grade gold intercepts drilled to date at the Panuco Project," commented Michael Konnert, President & CEO. "Our ongoing infill program, targeting the near-surface ultra high-grade zone at Copala continues to deliver exceptional silver and gold grades over very broad widths. In addition to confirmation of continuity, hole CS-24-356 also expanded high-grade mineralization closer to surface. Moving forward we will continue our conversion drilling at Copala as we de-risk the project ahead of the maiden PEA, slated for early Q3 2024."

06:04 EDT Nasdaq announces termination of previously announced agreement with EEX - Nasdaq announced the termination of its transaction agreement with the European Energy Exchange, previously announced on June 20, 2023, under which EEX had agreed to acquire Nasdaq's Nordic power trading and clearing business. Nasdaq continues to operate its Nordic power trading and clearing business and remains focused on providing its clients with exceptional service.

06:03 EDT High Tide to acquire Mississauga retail cannabis store for C$600,000 - High Tide has entered into a definitive asset purchase agreement dated June 25, 2024 pursuant to which High Tide will acquire a retail cannabis store in Mississauga, Ontario, currently operating as Cantopia for C$600,000. The store is located at 6400 Millcreek Drive, Mississauga and is situated in a bustling retail plaza surrounded by several small businesses. It is adjacent to an internationally recognized quick-serve restaurant and is steps away from a national discount retailer and a Canadian discount grocery chain. For the trailing three months ended May 31, 2024, the store generated annualized revenue of C$2.3 Million and annualized Adjusted EBITDA of C$0.4 Million. The purchase price represents 1.5x annualized Adjusted EBITDA for the trailing three months ended May 31, 2024. The Transaction, which is an arm's length transaction, is subject to, among other things, receipt of required TSX Venture Exchange approval, Alcohol and Gaming Commission of Ontario approval, and other customary conditions of closing, is expected to close in the coming weeks. The Consideration for the Stores being acquired will be C$600,000 paid in cash on the closing of the Transaction. The purchase price represents 1.5x annualized Adjusted EBITDA for the three months ended May 31, 2024. From the Consideration, an amount equal to approximately C$150,000 will be held in escrow for a period of twelve months by High Tide's lawyers to satisfy Cantopia's indemnity with respect to possible claims based on breaches of representation and warranties.

10:02 EDT Cedar Fair and Six Flags satisfy regulatory conditions for announced merger - Cedar Fair (FUN) and Six Flags Entertainment Corporation (SIX) announced that the regulatory conditions for their previously announced merger of equals have been satisfied, permitting the companies to proceed with the closing of the Mergers. The parties expect Closing to occur on July 1 following the satisfaction of remaining customary closing conditions. Immediately following the Closing, the combined company will be renamed "Six Flags Entertainment Corporation" and trading of the combined company's common stock on the New York Stock Exchange is expected to begin on July 2 under the ticker symbol "FUN."